MURC/Cavin-4 facilitates recruitment of ERK to caveolae and concentric cardiac hypertrophy induced by α1-adrenergic receptors The actions of catecholamines on adrenergic receptors (ARs) induce sympathetic responses, and sustained activation of the sympathetic nervous system results in disrupted circulatory homeostasis. In cardiomyocytes, α1-ARs localize to flask-shaped membrane microdomains known as "caveolae." Caveolae require both caveolin and cavin proteins for their biogenesis and function. However, the functional roles and molecular interactions of caveolar components in cardiomyocytes are poorly understood. Here, we showed that muscle-restricted coiled-coil protein (MURC)/Cavin-4 regulated α1-AR-induced cardiomyocyte hypertrophy through enhancement of ERK1/2 activation in caveolae. MURC/Cavin-4 was expressed in the caveolae and T tubules of cardiomyocytes. MURC/Cavin-4 overexpression distended the caveolae, whereas MURC/Cavin-4 was not essential for their formation. MURC/Cavin-4 deficiency attenuated cardiac hypertrophy induced by α1-AR stimulation in the presence of caveolae. Interestingly, MURC/Cavin-4 bound to α1A-and α1B-ARs as well as ERK1/2 in caveolae, and spatiotemporally modulated MEK/ERK signaling in response to α1-AR stimulation. Thus, MURC/Cavin-4 facilitates ERK1/2 recruitment to caveolae and efficient α1-AR signaling mediated by caveolae in cardiomyocytes, which provides a unique insight into the molecular mechanisms underlying caveola-mediated signaling in cardiac hypertrophy.
caveola | signal transduction | heart | plasma membrane C aveolae are plasmalemmal invaginations enriched in cholesterol, glycosphingolipids, and lipid-anchored proteins relative to the bulk of the plasma membrane (1, 2) . Owing to their specific lipid composition, caveolae concentrate several signaling molecules involved in cellular processes or trafficking events from the cell surface; therefore, they are recognized as a platform for preassembled complexes of receptors, signal components, and their targets, facilitating efficient and specific cellular responses (3) (4) (5) . Accumulating evidence has demonstrated that caveola biogenesis and function depend on two distinct caveolar components: caveolins and cavins (6, 7) . Caveolin (Cav)-1 and Cav-2 are expressed in most cell types, including adipocytes, endothelial cells, fibroblasts, and smooth myocytes, whereas Cav-3 is expressed exclusively in smooth, skeletal, and cardiac myocytes. Caveolin deficiency leads to caveolar loss, which is accompanied by alterations in signaling responses (8, 9) . Cavins are also structural components of caveolae and assume four isoforms, namely, polymerase I and transcript release factor (PTRF)/Cavin-1, serum deprivation protein response (SDPR)/Cavin-2, SDR-related gene product that binds to C kinase (SRBC)/Cavin-3, and muscle-related coiled-coil protein (MURC) (6) , which is also known as "Cavin-4" because of its sequence homology with other cavins and localization to the caveolae (10) . Previously, we reported the association of MURC/ Cavin-4 with SDPR/Cavin-2 and identified MURC/Cavin-4 mutations in dilated cardiomyopathy patients (11, 12) . PTRF/Cavin-1 and SDPR/Cavin-2 are expressed in various cell types, including myocytes (10, 11) , and SRBC/Cavin-3 is expressed in many cell types except for muscle cells (13) , whereas MURC/Cavin-4 is expressed exclusively in myocytes, similar to Cav-3 (11) . Recent studies have shown that cavins and caveolins form a complex, called the "caveolin-cavin complex," which modifies caveolar biogenesis and function (14, 15) . PTRF/Cavin-1 and SDPR/Cavin-2 are required for caveolar invagination and SRBC/Cavin-3 for caveolar budding to form caveolar vesicles (13, 16, 17) . However, the functional role of MURC/Cavin-4 in caveolar morphology is not known.
Alpha-1 adrenergic receptors (α1-ARs) are members of the G protein-coupled receptor (GPCR) family and have been demonstrated to accumulate in caveolar fractions of the myocardium (5) . GPCRs are well-known representatives of receptors concentrated in caveolae and transduce several signals from substrates to downstream effectors in caveolae (18) . Because disruption of the caveolae affects the response to several GPCRs, caveolae are considered important plasma membrane structures that coordinate GPCRs and their downstream signaling components (5) . In our previous study, we showed that MURC/Cavin-4 knockdown suppressed α1-AR agonist-induced atrial natriuretic peptide expression and myofibrillar organization in cardiomyocytes and that transgenic mice overexpressing MURC/Cavin-4 in cardiac tissue
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(MURC-Tg) developed cardiomyocyte hypertrophy at 5 wk of age (11) . These results suggest that MURC/Cavin-4 is involved in α1-AR signaling and cardiac hypertrophy.
In the present study, we manipulated MURC/Cavin-4 expression to investigate the role of MURC/Cavin-4 in caveolar morphology and α1-AR-induced cardiac hypertrophy. Overexpression and deletion of MURC/Cavin-4 showed the roles of MURC/Cavin-4 in the caveolar morphology of cardiomyocytes. Furthermore, we found that MURC/Cavin-4 facilitated ERK1/2 recruitment to caveolae and ERK activation in α1-AR-induced concentric cardiomyocyte hypertrophy.
Results
MURC/Cavin-4 Forms Caveolin-Cavin Complexes in the Caveolae and T Tubules and Modulates Caveolar Morphology in Cardiomyocytes. To reveal the functional significance of MURC/Cavin-4 as a caveolar component in cardiomyocytes, we examined the association of MURC/Cavin-4 with other cavins and caveolins. Expression plasmids encoding MURC/Cavin-4, Cav-3, and PTRF/Cavin-1 were transfected into CV-1 (simian) in origin, and carrying the SV40 genetic material (COS) cells, a fibroblast-like cell line derived from monkey kidney tissue. Immunoblot analysis showed that MURC/ Cavin-4 was coimmunoprecipitated with Cav-3 and PTRF/Cavin-1 ( Fig. S1 A and B) . MURC-HA and Cav-3-T7 expressions were not reduced in supernatants immunoprecipitated by anti-T7 and anti-HA antibodies, respectively (Fig. S1A) , whereas MURC-FLAG expression was reduced in the supernatant immunoprecipitated by the anti-HA antibody, although PTRF/Cavin-1-HA expression was not reduced in the supernatant immunoprecipitated by the anti-FLAG antibody (Fig. S1B) . These results suggest that MURC/Cavin-4 binds to PTRF/Cavin-1 with high affinity, and that MURC/Cavin-3 does not entirely bind to Cav-3.
The bimolecular fluorescence complementation (BiFC) assay confirmed that MURC/Cavin-4, Cav-3, PTRF/Cavin-1, and SDPR/ Cavin-2 interact in living cardiomyocytes ( Fig. S1 C and D) . Immunoelectron microscopy revealed that MURC/Cavin-4 was expressed in caveolae and T tubules in cardiomyocytes of adult mice (Fig. 1A) . These observations are in accordance with our previous finding showing that MURC/Cavin-4 was localized to the Z line in cardiomyocytes (11) because the T-tubule system is in register with the Z lines and the immunostaining pattern of Cav-3 has been shown to coincide with the Z line in the heart (19) . Because it was confirmed that MURC/Cavin-4 was expressed by caveolae, we assessed whether MURC/Cavin-4 affected caveolar morphology in cardiomyocytes. In cardiomyocytes of 13-wk-old MURC-Tg mice, the caveolae were significantly distended compared with those of wild-type (WT) mice (Fig. 1B) . The effects of MURC/Cavin-4 on caveolae were supported by the results of an in vitro study in which MURC/Cavin-4 overexpression significantly increased the caveolar area and perimeter in cardiomyocytes compared with β-galactosidase (LacZ) overexpression (Fig. 1C) . These results indicated that MURC/Cavin-4 modified the morphology of formed caveolae in cardiomyocytes.
MURC/Cavin-4 Is Associated with α1-ARs at Caveolae in Cardiomyocytes.
We next investigated the localization of α1-ARs in cardiomyocytes. α1-AR exists as three molecular subtypes: α1A, -B. and -D. The α1A and -B subtypes are expressed in the myocardium, whereas the α1D subtype is expressed in vascular muscle (20) . Because antibodies for α1-AR subtypes, which are frequently cited, have been shown to be nonspecific (21), we used plasmids encoding red fluorescent protein mCherry-conjugated α1A-AR (ADRA1A) and α1B-AR (ADRA1B). ADRA1A and ADRA1B signals were observed predominantly at the plasma membrane and partly within the cytoplasm ( Fig. 2A ). ADRA1A and ADRA1B signals were colocalized with endogenous Cav-3 and MURC/Cavin-4 at the plasma membrane and partly within the cytoplasm. Immunoprecipitation and BiFC assays revealed that both ADRA1A and ADRA1B were bound to MURC/Cavin-4 in COS cells and cultured rat cardiomyocytes, respectively ( Fig. 2 B and C) .
Because Cav-3 has also been demonstrated to bind to α1-ARs (22), we investigated whether Cav-3 could influence the localization of MURC/Cavin-4 and α1-ARs in cardiomyocytes. Cav-3 knockdown impaired the plasma membrane localization of MURC/ Cavin-4, resulting in the accumulation of MURC/Cavin-4 in the cytosol of cardiomyocytes (Fig. S2 A-C) . However, α1-ARs were retained at the plasma membrane in Cav-3-knocked down cardiomyocytes (Fig. S2A) . (Tables S1 and S2 ). Furthermore, caveolae and Cav-3 localization at the plasma membrane are retained in cardiomyocytes of MURC −/− mice ( Fig. S3 D and E), indicating that MURC/Cavin-4 is not essential to the membrane localization of Cav-3 and caveola formation in cardiomyocytes. Phenylephrine (PE) infusion for 7 d caused marked concentric cardiac hypertrophy in WT mice, whereas MURC/Cavin-4 depletion suppressed cardiac hypertrophy, as evaluated using a crosssectional area (Fig. 3A) . Morphological and echocardiographic analyses also showed attenuated cardiac hypertrophy in MURC −/− mice (Tables S1 and S2 ). In the hearts of MURC −/− mice, BNP and βMHC mRNA expression levels were reduced in response to PE, compared with those of WT mice (Fig. 3B) . A previous study demonstrated that, in ADRA1A and ADRA1B double-knockout (KO) (α1AB-KO) mice, ERK activation was reduced and PE could not activate ERK in cardiomyocytes, resulting in a reduced heart size in α1AB-KO mice compared with that in male WT mice (23) . Therefore, we investigated ERK activation in WT and MURC −/− hearts. After PE infusion for 2 d, ERK activation was significantly suppressed in the hearts of MURC −/− mice compared with WT mice (Fig. 3C) . In neonatal mouse cardiomyocytes isolated from WT and MURC −/− mice, PE-induced ERK activation was also significantly suppressed in MURC −/− cardiomyocytes compared with the level in WT cardiomyocytes (Fig. S3F) . Mitogen-activated protein kinases (MAPKs), including ERK1/2, modulate cardiac hypertrophy through G proteins (24) . Therefore, we assessed p38 and JNK activities in the hearts of WT and MURC −/− mice (Fig. S3G) . The basal activity of p38 did not differ between WT and MURC −/− hearts, whereas JNK activation was significantly increased in MURC −/− hearts compared with the level in WT hearts. However, both p38 and JNK activities were not enhanced by PE infusion in the hearts of WT and MURC −/− mice. To clarify the molecular mechanisms responsible for MURC/ Cavin-4-mediated cardiac hypertrophy, we knocked down MURC expression in neonatal rat cardiomyocytes. PE increased MURC/ Cavin-4 mRNA expression in cardiomyocytes, whereas MURC/ Cavin-4 RNA interference (RNAi) using Ad-rMURC short hairpin RNA (shRNA) attenuated PE-induced MURC/Cavin-4 mRNA expression (Fig. S4A ). MURC/Cavin-4 RNAi reduced PE-induced increases in cell size and BNP mRNA expression ( Fig. S4 B and C), which is consistent with the in vivo study described above. PE-induced ERK activation was also suppressed in neonatal rat cardiomyocytes infected with Ad-MURC-shRNA as well as mouse cardiomyocytes isolated from MURC −/− mice (Fig. 4A) . In cardiomyocytes infected with Ad-Luc-shRNA, ERK activation was detected 5 min after PE stimulation, which peaked at 30 min and then declined, whereas in cardiomyocytes infected with Ad-MURC-shRNA, ERK activation peaked at 5 min and then declined, which was significantly suppressed compared with that in Ad-Luc-shRNA-infected cardiomyocytes, suggesting that MURC/Cavin-4 plays a determinant role in the modulation of signaling amplitude and the duration of ERK activation in response to PE stimulation.
A previous study using immunoelectron microscopy showed that ERK was concentrated in caveolae (25) . ERK is activated at the plasma membrane by several GPCRs and subsequently translocates to the nucleus and cytoplasm (26) . Therefore, we investigated the functional role of MURC/Cavin-4 in ERK localization. In unstimulated cardiomyocytes, total and phosphorylated ERK was distributed throughout the cytoplasm and partially at the plasma membrane, where it was colocalized with MURC ( Fig. 4B ). Upon PE stimulation, both MURC/Cavin-4 and phosphorylated ERK were translocated from the plasma membrane to the perinuclear region ( Fig. 4 B and C) . MURC/Cavin-4 knockdown reduced phosphorylated ERK accumulation at the plasma membrane (Fig.  4D ). Immunoblot analysis showed that MURC/Cavin-4 coimmunoprecipitated with phosphorylated and total ERK (Fig. 4E) .
The stability of ERK proteins influences the duration of ERK activity (27) . Thus, we evaluated the stability of phosphorylated and total ERK using cycloheximide (CHX), a protein biosynthesis inhibitor. The stability of phosphorylated and total ERK proteins was significantly increased following CHX treatment in MURC-expressing cardiomyocytes compared with the level in those expressing LacZ (Fig. S4D ). 
MURC/Cavin-4 Modulates α1-AR-Induced Cardiomyocyte Hypertrophy
Through ERK Activation. We previously demonstrated cardiomyocyte hypertrophy in young MURC-Tg mice (11) . In the present study, we found that ERK activity was increased in the cardiomyocytes of 6-wk-old MURC-Tg mice ( overexpression in response to PE stimulation. Taken together, these findings suggested that MURC/Cavin-4 was capable of regulating ERK activation in a MEK1/2-dependent and -independent manner and that MURC/Cavin-4 served as a caveolar platform, thereby allowing activated α1-ARs to elicit MEK1/2 activation efficiently.
Discussion
Similar to caveolins, cavins are caveolar components that modulate caveolar morphology (29) . Among the cavins, PTRF/Cavin-1 is required for caveola formation in various cell types including epithelium, smooth muscle, and skeletal muscle (16, 30) . A recent study showed that SDPR/Cavin-2 deletion caused a pronounced reduction in caveola abundance in lung endothelium, but not in heart endothelium and that SRBC/Cavin-3 deletion did not affect caveolar formation in these cells (31) . We demonstrated in the present study that MURC/Cavin-4 modified the morphology of formed caveolae in cardiomyocytes, whereas MURC/Cavin-4 was not essential to caveolar formation. Thus, all cavin proteins do not necessarily have the ability to form caveolae. Cav-3 KO mice showed a loss of caveolae in cardiomyocytes, leading to ERK activation and cardiac hypertrophy (19) . We showed that Cav-3 knockdown reduced MURC/Cavin-4 localization at the plasma membrane, whereas MURC/Cavin-4 deficiency did not impair the membrane localization of Cav-3. Furthermore, unlike Cav-3 KO mice, MURC/Cavin-4-deficient mice exhibit normal caveolar morphology and function under physiological conditions. MURC/ Cavin-4 deficiency attenuated ERK activation and cardiac hypertrophy induced by α1-AR stimulation. These results indicate that MURC/Cavin-4 regulates ERK activity and cardiac hypertrophy independently of caveolar morphology. MURC/Cavin-4 bound to ERK1/2 in cardiomyocytes, and MURC/Cavin-4 and phosphorylated ERK were cotranslocated from the plasma membrane to the perinuclear region in response to PE. MURC/Cavin-4 knockdown attenuated PE-induced phosphorylated ERK accumulation at the plasma membrane. These findings suggest that MURC/Cavin-4 interacts with ERK and promotes ERK recruitment to caveolae and subsequent internalization by the caveolae. We also showed that MURC/Cavin-4 increased the stability of phosphorylated and total ERK proteins in cardiomyocytes, which suggests that MURC/Cavin-4 stabilized ERK proteins to prevent their inactivation and/or degradation, thereby sustaining ERK activation. Although scaffold proteins involved in ERK signaling, such as kinase suppressor of Ras (KSR), MAPK kinase (MEK) partner 1, MAPK organizer 1, and β-arrestin, have been identified (32) , the relationship between these scaffolds and the caveolae has not been documented. Our results provide the unique documentation that MURC/Cavin-4 is a scaffold protein for ERK in caveolae and contributes to the stabilization of ERK activity in cardiomyocytes. Thus, MURC/ Cavin-4 spatiotemporally regulates α1-AR-induced ERK activation in cardiomyocytes.
Several studies have demonstrated that α1-ARs were localized to the plasma membrane (19, 33, 34) , whereas Wright et al. (35) showed that α1-ARs were located around or within the nucleus, but not on the plasma membrane, in adult mouse cardiomyocytes. Thus, controversy exists regarding the localization of α1-ARs in cardiomyocytes. Because of a lack of proper antibodies for α1-AR subtypes (21), we expressed fluorescent protein-tagged α1-ARs in cardiomyocytes and showed that α1A-and α1B-ARs were colocalized with MURC/Cavin-4 and Cav-3 at the plasma membrane and partly within the cytoplasm in cardiomyocytes. It has been revealed that many GPCRs form oligomeric complexes, as either homo-or heterooligomers, and that GPCR oligomerization has effects on ligand binding, receptor activation, desensitization, and trafficking, as well as receptor signaling (21) . We showed that MURC/Cavin-4 enhanced MEK1/2 activation in response to PE stimulation in cardiomyocytes. Because MURC/ Cavin-4 interacts with α1A-and α1B-AR, our observations raise the possibility that MURC/Cavin-4 might contribute to an increase in the accessibility between each of the α1-ARs, which leads to α1-AR oligomerization and promotes α1-AR signaling. A previous study reported that MEK1 was distributed in caveolae (25) . On the basis of this evidence, we predicted that MURC/Cavin-4 interacted with MEK1/2 as well as ERK in the caveolae, although coimmunoprecipitation analysis did not demonstrate an association between MURC/Cavin-4 and MEK1/2. Considering that MURC/ Cavin-4 is colocalized with α1-ARs, MURC/Cavin-4 may also contribute to the functional compartmentation of α1-AR signaling of the caveolae, which facilitates the responsiveness of MEK1/2 activation in response to α1-AR stimulation, although MURC/ Cavin-4 does not interact with MEK1/2 directly.
In cultured cardiomyocytes, ERK depletion using an antisense oligonucleotide was shown to down-regulate PE-induced hypertrophic responses (36) . In the present study, ERK1/2 knockdown inhibited MURC/Cavin-4-and PE-induced cardiomyocyte hypertrophy. Thus, ERK has a crucial role in α1-AR-and MURC/ Cavin-4-induced cardiac hypertrophy. Furthermore, MURC/ Cavin-4 knockdown inhibited PE-induced cardiomyocyte hypertrophy associated with ERK inactivation. These findings suggested that MURC/Cavin-4 mediated PE-induced ERK signaling in cardiomyocytes.
Although the role of ERK signaling in cardiomyocyte hypertrophy is unknown (37), activated MEK1 induced concentric cardiac hypertrophy with ERK1/2 activation in transgenic mice (28) . ERK1/2-deficient mice showed increases in the heart:body weight ratio and reductions in cardiac contractility under physiological conditions, which resulted in eccentric hypertrophy and cardiomyocyte elongation (38) . Furthermore, angiotensin II and PE stimulation worsened eccentric cardiac growth in ERK1/2-deficient mice. However, in our present study, 1 wk of PE infusion inhibited concentric hypertrophy in MURC −/− mice, but did not promote eccentric hypertrophy, despite the inhibition of ERK activation. The discrepancy between these studies may be explained by a difference in the levels of suppressed ERK activity. Eccentric hypertrophy and cardiomyocyte elongation were observed in ERK1/2-deficient mice, which have complete loss of ERK activity (38) . On the other hand, MURC/Cavin-4 deficiency maintained baseline ERK activity in the cardiomyocytes compared with that in control mice under physiological conditions. These observations suggested that concentric hypertrophy was modulated by ERK activation, which is induced by various stimuli, and that eccentric hypertrophy was modulated by a reduction in basal ERK activity.
As shown in the present study, although MURC/Cavin-4 is dispensable for caveolar formation in cardiomyocytes, MURC/ Cavin-4 serves as an ERK-recruiting protein in the caveolae within cardiomyocytes. The recruiting function of MURC/Cavin-4 is necessary to elicit efficient signaling of the α1-AR/ERK cascade in the caveolae in concentric cardiac hypertrophy, which provides unique insight into the molecular mechanisms underlying caveolamediated signaling in cardiac hypertrophy.
Materials and Methods
Pearson product-moment correlation coefficient was used to measure the linear correlation between variables. All experiments were performed at least thrice. Data are expressed as mean ± SEM and were analyzed by one-way ANOVA with post hoc analysis. A P value of <0.05 was considered significant.
The other materials and methods used for this study are described in SI Materials and Methods.
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Transmission Electron Microscopy and Quantitation. Twelve-and 20-wk-old mouse hearts and adult rat cardiomyocytes were fixed with 2% (vol/vol) glutaraldehyde (GA) in 0.1 M cacodylate buffer, postfixed with 2% OsO 4 , and stained with uranyl acetate and lead citrate. For preembedding immunogold election microscopy, tissue sections were washed with PBS and fixed with 4% (wt/vol) paraformaldehyde (PFA)/PBS for 2 h at 4°C. The sections were then permeabilized in PBS containing 0.5% saponin for 1 h at 4°C. After blocking, the sections were incubated in 5% (wt/vol) BSA, 5% (wt/vol) normal goat serum, and 0.1% cold fish gelatin in 0.1 M PBS for 30 min at 4°C and then incubated in rabbit anti-muscle-restricted coiled-coil protein (MURC)/Cavin-4 antibody (1:100 dilution) for 18 h at 4°C, washed in incubation buffer and incubated with goat anti-rabbit IgG conjugated to 10-nm gold particles (1:100 dilution) for 2 h at room temperature. Tissue sections were washed and finally fixed with 2% GA in 0.1 M cacodylate buffer and postfixed with 2% OsO 4 . Microtome sections were examined using an H-7100 (Hitachi) or a JEM-1200EX (JEOL, Ltd.) transmission electron microscope and photographed at a magnification of 40,000× or 20,000×. Caveolae were identified by their characteristic flask shapes and locations at or near the plasma membrane. When the caveolar perimeter or area was measured, two independent fields from each of at least two independent experiments were quantitated for each condition. Similar results were obtained in double-blind experiments.
Neonatal and Adult Cardiomyocyte Culture. Rat and mouse neonatal cardiomyocytes, cultured from 1-d-old Wistar rats and C57BL6 mice, were prepared as described previously with slight modifications (1-3). Isolated neonatal cardiomyocytes were cultured in serum-containing medium for 24 h and then cultured in serum-free medium. For electron microscopic analysis, adult rat cardiomyocytes were isolated from 8-wk-old male Wistar rats as described previously with minor modifications (4). Adult myocytes were plated on laminin-coated plates and cultured in DMEM-Ham's F-12 nutrient mixture with 5% (vol/vol) newborn calf serum for 1 h. The media were changed to serum-free media (1% BSA, insulin-transferrin-selenium-ethanolamine) to remove nonmyocytes and the cardiomyocytes were incubated at 37°C in an atmosphere of 5% CO 2 .
Plasmid Construction. The corresponding cDNA fragments for human MURC/Cavin-4, alpha-1 (α1) A-and α1B-adrenergic receptor (AR) (ADRA1A and ADRA1B), were cloned by PCR from a human heart cDNA template as previously described (1) . Complemetnary DNA (cDNA) encoding human MURC/Cavin-4 with a C-terminal anti-DYKDDDDK (FLAG) or HA epitope and human ADRA1A with a C-terminal HA epitope were cloned into pcDNA3.1 (Invitrogen) to generate pcDNA3.1-MURC-FLAG or -HA and pcDNA3.1-ADRA1A-HA, respectively. The cDNA encoding human ADRA1A was cloned into pEGFP-N3 (Clontech), whereas pmCherry-ADRA1A and -ADRA1B were generated by replacing the EGFP gene with the mCherry gene cloned by PCR from pmCherry-C1 (Clontech) as a template. Myc-DDKtagged human ADRA1B (pCMV6-Myc-DDK-ADRA1B) was purchased from OriGene Technologies, Inc. HA-tagged human polymerase I and transcript release factor (PTRF), pCruz-HA-A-PTRF, T7-tagged human Caveolin (Cav)-3, and pcDNA3.1-Cav-3-T7 were previously described (5) . To construct mammalian expression vectors for the bimolecular fluorescence complementation (BiFC) assay, the cDNA fragments of human MURC/Cavin-4, Recombinant adenoviruses expressing FLAG-tagged mouse MURC/Cavin-4 (Ad-MURC), Ad-β-galactosidase (Ad-LacZ), rMURC/Cavin-4 short hairpin RNA (shRNA) (Ad-rMURC shRNA), and luciferase shRNA (Ad-Luc shRNA) were described previously (1) . Twenty-four hours after seeding, the cardiomyocytes were infected with Ad-MURC, Ad-LacZ, AdrMURC shRNA, or Ad-Luc shRNA diluted in culture media at a multiplicity of infection of 10 or 20 and incubated at 37°C for 1 h. The viral suspension was removed and the cardiomyocytes were cultured with serum-depleted culture media. Phenylephrine (PE) was added postinfection.
Generation of MURC −/− Mice and Cardiospecific MURC Transgenic
Mice. Genomic MURC DNA was isolated from R1 ES cells and used to create a MURC-targeting construct containing floxP sites and the neomycin resistance gene. The construct was generated in the pBluescript II KS + vector. The 5′ arm of homology consisted of the first floxP site located in the 5′ untranslated region of MURC exon 1. The 3′ arm of homology consisted of a 2.2-kb fragment fused with the FRT-Neo-FRT-floxP cassette located downstream of MURC exon 1. The targeting construct was verified by sequencing and linearized with the NotI endonuclease before electroporation into R1 ES cells. Genomic DNA was extracted from G418-resistant ES cell clones. ES cell DNA was digested with the NdeI and SpeI endonucleases and subjected to Southern blot analysis. For the 5′ probe, a 500-bp fragment was PCR-generated using genomic mouse DNA and specific MURC primers [forward (F), AGTCCTGTCAGCC-TAAAATAGGAGT; reverse (R), CTCATTCATACTCATCA-GACCACTT]. For the 3′ probe, a 458-bp fragment was PCRgenerated using specific MURC primers (F, CAGGTCAA-GAGCTTTCTAAGCATAC; R, TCTAACTATAGCACAGG-CACCTCTC). The PCR products were subsequently radiolabeled with α-[ 32 P] deoxycytidine triphosphate by random priming (Invitrogen). DNA blots were hybridized with the radiolabeled probes and visualized by autoradiography. The wld-type (WT) allele was represented by a 21.1-kb band, whereas a 9.9-or a 12.9-kb band represented the correctly targeted alleles. Five of 300 G418-resistant ES clones that underwent homologous recombination were identified by Southern blot analysis. Two independent homologous recombinant ES clones were microinjected into blastocysts derived from C57BL/6 mice. Male chimeras were inbred with female C57BL/6 mice to generate germ line-transmitted heterozygous mice (MURC fl/+ mice). To induce MURC −/− mice, MURC fl/+ mice were bred with those expressing the CAG promoter-driven cre recombinase gene. Offspring were genotyped by PCR analysis using mouse tail DNA and primers (F, CGGA-TTGCCATAGGACACCTTCTGC; R, TTAAATAGTGAGGG-TTAGGTCACCA).
Transgenic mice expressing MURC in the heart (MURC-Tg) were described previously (1). All aspects of animal care and experimentation performed in this study were approved by the Institutional Animal Care and Use Committee of Kyoto Prefectural University of Medicine.
Immunoprecipitation. CV-1 (simian) in origin, and carrying the SV40 genetic material (COS) cells were plated in 60-mm dishes and cotransfected with pcDNA3.1-MURC-FLAG and/or pCruz-HA-A-PTRF with pcDNA3.1-MURC-HA, and/or pcDNA3.1-Cav-3-T7 with pcDNA3.1-ADRA1A-HA, and/or pcDNA3.1-MURC-FLAG with pcDNA3.1-MURC-HA, and/or pCMV6-Myc-DDK-ADRA1B. Cardiomyocytes were also plated in 60-mm dishes and infected with or without Ad-MURC. Cells were cultured for an additional 48 h and lysed with lysis buffer [50 mM Tris·HCl (pH 7.5), 150 mM NaCl, 50 mM EDTA, 1% Triton X-100, 1 mM phenylmethanesulfonylfluoride (PMSF), protease inhibitor mixture (Pierce Biotechnology), 1 mM Na 3 VO 4 , 1 mM NaF, and 60 mM octyl glucoside]. Monoclonal antibodies against FLAG M2 (SigmaAldrich), HA (Roche Diagnostics), T7 (Novagen Biosciences, Inc.), ERK1/2 (Cell Signaling Technology, Inc.), or phospho-ERK1/2 (p-ERK1/2; Cell Signaling Technology, Inc.) were conjugated to magnosphere MS300/carboxyl beads (JSR Micro) according to the manufacturer's protocol. Cell lysates were incubated with antibody-conjugated beads for 3 h at 4°C. After the beads were extensively washed with the lysis buffer, the bound proteins were eluted by boiling the beads in SDS sample buffer and then subjected to SDS/PAGE followed by Western blot analysis.
Protein-Protein Interaction Assay. To examine the interaction of target proteins in living cardiomyocytes, we performed the BiFC assay using the CoralHue Fluo-Chase kit (MBL International) as described previously (6, 7) . In brief, cardiomyocytes were cotransfected with plasmid pairs expressing the target proteins fused to divided mKG fragments. Three days after transfection using Lipofectamine LTX (Invitrogen), cardiomyocytes were observed by fluorescence microscopy. When a target protein fused to the N-terminal portion of the mKG fragment was associated with another target protein fused to the C-terminal portion of the mKG fragments, which formed a steric structure before dividing, the chromophore emitted fluorescence. ) or PBS (control) were surgically inserted dorsally and s.c. in 2-mo-old mice under isoflurane anesthesia. Seven days later, we performed echocardiography using a Vevo 2100 system (VisualSonics) equipped with a 30-MHz microprobe under isoflurane anesthesia. After echocardiography, the mice were killed by cervical dislocation and then weighed. Hearts were excised, rinsed in PBS, and weighed. The body weight or the left tibial length was measured to normalize the heart weight. For analysis of ERK activation, other mice were killed 2 d after surgery.
Histological Analysis. Cardiac perfusion-fixation was performed using 4% PFA/PBS. The hearts were sectioned and stained with hematoxylin/eosin (H&E).
RT-Quantitative PCR. Total RNA was extracted from cells or tissues using the RNeasy Mini Kit (Qiagen) or TRIzol reagent (Invitrogen). cDNA synthesis and kinetic real-time PCR were performed as described previously (1, (8) (9) (10) . The primer sequences were as follows: mouse BNP (F, CTGAAGGTGCTGTCCCA-GAT; R, CCTTGGTCCTTCAAGAGCTG); mouse αMHC (F, GAGGACCAGGCCAATGAGTA; R, GCTGGGTGTAGGA-GAGCTTG); mouse βMHC (F, GGAGCTCACCTACCAGA-CAGA; R, CTCAGGGCTTCACAGGCATCC); mouse GAPDH (F, TTGTGATGGGTGTGAACCACGAGA; R, CATGAGCC-CTTCCACAATGCCAAA); rat MURC/Cavin-4 (F, ACTGAA-GATGAAGACCAGGACGCA; R, TGTTAACAACGTAGCC-CGTGTTGC); rat BNP (F, GGAAATGGCTCAGAGACAGC; R, CGATCCGGTCTATCTTCTGC); and rat GAPDH (F, ATGG-GAAGCTGGTCATCAAC; R, GTGGTTCACACCCATCACAA).
Measurement of Cardiomyocyte Size. Cardiomyocytes were infected with Ad-LacZ or Ad-MURC, and 24 h later the cells were treated with or without U0126 [a highly selective inhibitor of both mitogenactivated protein kinase kinase (MEK) 1 and MEK2] for 48 h. After fixation with 4% PFA, the cells were stained with FITC (SigmaAldrich) and DAPI (Invitrogen). Cells were imaged using an immunofluorescence microscope and measured using Image J software (National Institutes of Health, Bethesda). At least 50 cells were measured per sample.
Western Blot Analysis. Cell lysates and tissue samples were extracted using a lysis buffer containing 50 mM Tris·HCl (pH 7.5), 150 mM NaCl, 50 mM EDTA, 1% Triton X-100, 1 mM PMSF, protease inhibitor mixture, 1 mM Na 3 VO 4 , and 1 mM NaF. Protein samples were then subjected to SDS/PAGE. Transferred membranes were subsequently incubated with primary polyclonal antibody against MURC and monoclonal antibodies against FLAG M2, HA, T7, p-ERK1/2, ERK1/2, phospho-MEK (p-MEK; Cell Signaling Technology, Inc.), MEK (Cell Signaling Technology, Inc.), Na-K ATPase α1 subunit (Santa Cluz Biotechnology, Inc.), or glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Chemicon International, Inc.). Horseradish peroxidase-conjugated anti-rabbit, -rat and -mouse IgG (GE Healthcare) were used as secondary antibodies.
Preparation of Cytosol or Membrane Fraction. Cell fractionation was performed as previously described (7). In brief, cells were harvested from the 100-mm culture dishes and resuspended in icecold homogenization buffer containing 250 mM sucrose, 20 mM phosphate buffer (pH 6.8), and a protease/phosphatase inhibitor mixture (Thermo Fisher Scientific Inc.). Cells were homogenized gently on ice using a Dounce tissue grinder (Sigma-Aldrich) and centrifuged at 1,000 × g for 10 min to remove nuclei and remaining cells. The supernatants were ultracentrifuged at 55,000 rpm for 30 min using an Optima TLX centrifuge (Beckman Coulter, Inc.) with a TLA-100.3 rotor. Supernatants were obtained as the cytosol fraction. Pellets were lysed with the lysis buffer and centrifuged, and the supernatants were obtained as the membrane fraction.
Protein Stability Assay. We assessed p-ERK1/2 or ERK1/2 protein stability using cycloheximide (CHX), an inhibitor of protein synthesis, as described previously (11) . Cells were exposed to 50 μM CHX for 36 h and protein expression was analyzed by Western blot analysis.
Immunofluorescence Microscopy. Specimens were fixed in 4% PFA/PBS and stained with rabbit polyclonal MURC/Cavin-4 antibody, mouse monoclonal anti-Cav-3 antibody (BD Biosciences), mouse monoclonal anti-FLAG M2 antibody, mouse monoclonal anti-p-ERK1/2 antibody, or rabbit polyclonal anti-MURC/Cavin-4 antibody. Secondary antibodies were conjugated with Alexa Fluor 488, 555, or 594, and nuclei were visualized using DAPI.
Gene Silencing Through RNA Interference. Rat ERK1-and ERK2-specific and control siRNA duplex oligonucleotides [Stealth RNA interface (RNAi)] were purchased from Invitrogen. siRNAs were transiently transfected into cardiomyocytes using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer's protocol. The medium was changed 4 h posttransfection and cardiomyocytes were harvested or fixed for 72 h after transfection. The siRNA sequences were as follows: ERK1 siRNA-1 [sense (S), 5′-CAGCUGAGCAAUGACCACAUCUGCU; antisense (AS), 5′-AGCAGAUGUGGUCAUUGCCAGCUG]; ERK1 siRNA-2 (S, 5′-CCAGCUCAACCACAUUCUAGGUAUA; AS, 5′-UAUACCUAGAAUGUGGUUGAGCUGG); ERK2 siRNA-1 (S, 5′-CCCUCACAAGAGGAUUGAAGUUGAA; AS, 5′-UUCAACUUCAAUCCUCUUGUGAGGG); and ERK2 siRNA-2 (S, 5′-CCACCCGUACCUGGAGCAGUAUUAU; AS, 5′-AUAAUACUGCUCCAGGUACGGGUGG). 28.7 ± 6.1 EF, % 53.6 ± 1.9 55.9 ± 3.2 56.4 ± 6.5 55.7 ± 7.6 EF, ejection fraction; FS, fractional shortening; IVSTd, interventricular septum thickness at end-diastole; LVDd, left ventricular dimension at end diastole; LVDs, left ventricular dimension in systole; PWTd, left ventricular posterior wall thickness at end-diastole. Values are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 compared with WT-sham mice.
† P < 0.05 and † † P < 0.01 compared with WT-PE mice. 
